Home › Calculator › BIOVF Dividend Calculator 2026
BIOVF Dividend DRIP Calculator 2026
4.17% YieldHealthcareSwedish Orphan Biovitrum AB (publ) · OTC
Price: $48.00 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When BIOVF pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your BIOVF snowball 📈
$10,000 in BIOVF → $1.63M in 10 years · $36.96/month
About Swedish Orphan Biovitrum AB (publ) (BIOVF) — Dividend Analysis 2026
Operating under the ticker BIOVF, Swedish Orphan Biovitrum AB (publ) is a specialized biotechnology company dedicated to the research, development, manufacturing, and commercialization of pharmaceutical products. Its primary therapeutic focus areas encompass hematology, immunology, and a range of genetic and metabolic disorders, with a commercial presence across Europe, North America, and other international markets. The company's diverse portfolio includes medications addressing critical conditions such as hemophilia B (Alprolix) and hemophilia A (Elocta), thrombocytopenia (Doptelet), hemophagocytic lymphohistiocytosis (Gamifant), and hereditary tyrosinemia type-1 (Orfadin). Additionally, it provides Kineret for multiple inflammatory diseases, including cryopyrin-associated periodic syndrome, rheumatoid arthritis, and Still's disease, alongside Synagis for severe lower respiratory tract infections. Sobi's broader product range further comprises various other therapeutics like Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. Beyond its proprietary offerings, Sobi is involved in the development of drug substances for external partners, notably ReFacto AF/Xyntha for Pfizer, as well as advancing BIVV001 for hemophilia A and Nirsevimab, which targets respiratory syncytial virus. A key strategic collaboration exists with Apellis Pharmaceuticals Inc. for the co-development of pegcetacoplan, aimed at treating a spectrum of rare diseases, such as paroxysmal nocturnal hemoglobinuria. The company maintains its headquarters in Solna, Sweden.
Compare BIOVF with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full BIOVF DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open BIOVF position with:
🌍 BIOVF Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold BIOVF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 4.17% | 1.37% | $417 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 3.54% | 0.74% | $354 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 3.34% | 0.54% | $334 / yr |
| 🇬🇧 UK ISA | 0% | 4.17% | 1.37% | $417 / yr |
| 🇬🇧 UK Taxable | 8.75% | 3.81% | 1.01% | $381 / yr |
| 🇨🇦 TFSA | 0% | 4.17% | 1.37% | $417 / yr |
| 🇨🇦 CA Taxable | 25% | 3.13% | 0.33% | $313 / yr |
| 🇦🇺 Super (pension) | 15% | 3.54% | 0.74% | $354 / yr |
| 🇦🇺 AU Taxable | 30% | 2.92% | 0.12% | $292 / yr |
| 🇩🇪 DE Taxable | 26.375% | 3.07% | 0.27% | $307 / yr |
| 🇫🇷 FR Taxable | 30% | 2.92% | 0.12% | $292 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 BIOVF Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 BIOVF Dividend Payment Schedule
BIOVF pays quarterly — 4 times per year. Next ex-div: TBD.
📊 BIOVF vs Healthcare Benchmarks
How BIOVF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for BIOVF sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ BIOVF Insider Activity
No recent SEC filings reported in the last 90 days.Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the BIOVF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Swedish Orphan Biovitrum AB (publ) (BIOVF) is currently trading at $48.00, trading near its 52-week high. The current dividend yield is 4.17% based on an annual payout of $2.00 per share.
BIOVF (Swedish Orphan Biovitrum AB (publ)) — 4.17% Dividend Yield Analysis
Swedish Orphan Biovitrum AB (publ) (BIOVF) is a healthcare stock currently trading at $48.00 with a dividend yield of 4.17%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Dividend payments are not guaranteed and can be reduced or suspended at any time.
Auto-generated from live market data. For educational purposes only — not financial advice.